Somewhat Favorable Press Coverage Somewhat Unlikely to Impact Celator Pharmaceuticals (CPXX) Stock Price
Media coverage about Celator Pharmaceuticals (NASDAQ:CPXX) has trended somewhat positive on Sunday, Accern Sentiment Analysis reports. The research firm rates the sentiment of press coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Celator Pharmaceuticals earned a daily sentiment score of 0.05 on Accern’s scale. Accern also assigned press coverage about the company an impact score of 43.1822460113896 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
Celator Pharmaceuticals Company Profile
Celator Pharmaceuticals, Inc is an oncology-focused biopharmaceutical company. The Company is engaged in developing products to improve patient outcomes in cancer. The Company’s technology platform, CombiPlex, enables the design and evaluation of optimized combinations incorporating traditional chemotherapies, as well as molecularly targeted agents to deliver anti-cancer activity.
Receive News & Ratings for Celator Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celator Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.